Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
89
days
Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis
Authors
Aisling McGuigan; Hannah A. BlairShow moreShow less
Affiliations
1. Springer Nature, Auckland, New ZealandShow moreShow less
285
days
Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials
Authors
Itai Danovitch; Kyla Truman; Haze Brown; Macie Miller; Shaishav Shah; Jayant Totlani; Daniel N. Kaidbay; Kaleab K. Tessema; Zholi Minasyan; Waguih William IsHak; Samuel Miles; Robert N. PechnickShow moreShow less
Affiliations
1. Department of Psychiatry, Cedars-Sinai Health Sciences University, Los Angeles, USA; 2. David Geffen School of Medicine at UCLA, Los Angeles, USA; 3. Virginia Commonwealth University Health System, Richmond, USA; 4. Western University of Health Sciences, Pomona, USAShow moreShow less
117
days
Bistromathics in Epilepsy and the Relativity of Numbers
Authors
Emilio Russo; Roberta Roberti; Eugen TrinkaShow moreShow less
Affiliations
1. Science of Health Department, CRUISE Research Center, University Magna Grecia of Catanzaro, Catanzaro, Italy; 2. Department of Neurology, Neurocritical Care and Neurorehabilitation, Member of EpiCARE, Christian Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria; 3. Neuroscience Institute, Christian Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria; 4. Karl Landsteiner Institute for Clinical Neurosciences, Salzburg, AustriaShow moreShow less
156
days
Cognitive Side Effects of Antiseizure Medications in Adults with Epilepsy: An Update with a Focus on New Therapeutic Agents
Authors
Marco MulaShow moreShow less
Affiliations
1. Department of Neurology, Atkinson Morley Regional Neuroscience Centre, St George’s University Hospitals, London, UKShow moreShow less
160
days
Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms
Authors
Alana King; Morgan Hardy; Taeho Greg Rhee; Samuel T. WilkinsonShow moreShow less
Affiliations
1. Department of Psychiatry, Yale University, New Haven, USAShow moreShow less
55
days
Emerging Pharmacological Strategies for Trigeminal Neuralgia
Authors
Juliana Geremias Chichorro; Victor Augusto Benedicto dos Santos; Gerald W. ZamponiShow moreShow less
Affiliations
1. Department of Pharmacology, Biological Sciences Sector, Federal University of Parana, Curitiba, Brazil; 2. Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, CanadaShow moreShow less
FAQ
How long does CNS DRUGS take to review a manuscript?
As of 2026-11-18, CrushSCI has 15 complete review records for CNS DRUGS. The fastest paper went from submission to acceptance in 55 days (Emerging Pharmacological Strategies for Trigeminal Neuralgia, received 2026-04-02, accepted 2026-05-27); the slowest took 285 days. The average is 171.6 days and the median is 156 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
